Major Facebook ad glitch has advertisers asking about refunds
The glitch caused many companies to fund Facebook ad campaigns that were essentially ineffective.
Mortgage demand rebounds, even as interest rates hit the highest level in over a month
Mortgage demand rebounded despite a rise in interest rates, as homebuyers take advantage of easing house prices.
Illumina unveils plans to cut costs as it faces shrinking margins
The plans aim to reduce Illumina’s annualized run rate expenses by more than $100 million starting later this year.
The banking crisis is having a slow-burn impact on the economy
The money pipeline to Wall Street remains mostly alive and well while the situation on Main Street is much more in flux.
How to trade Apple’s March quarter results based on history
Using data going back 10 years, Morgan Stanley found how well the stock performs against the S&P 500 based on different outcomes from the March quarter report.
Biogen isn’t concerned about competing with Eli Lilly in the Alzheimer’s drug space, CEO says
Biogen CEO Christopher Viehbacher said during an earnings call that Eli Lilly needs to consider maintenance doses its Alzheimer’s treatment donanemab.
FDA grants accelerated approval for Biogen ALS drug that treats rare form of the disease
The FDA’s approval requires Biogen to further study its ALS drug tofersen to further verify its clinical benefits.
U.S. regulators warn they already have the power to go after A.I. bias — and they’re ready to use it
Four federal U.S. agencies issued a warning on Tuesday that they already have the authority to tackle harms caused by AI bias.
Mpox outbreak was wake-up call for smallpox preparation, vaccine maker Bavarian Nordic says
Bavarian Nordic plans to sharply scale up production of its Jynneos vaccine to prepare for a smallpox emergency, CEO Paul Chaplin said.
How the U.S. built a junk fee economy
Americans are collectively spending nearly $65 billion on junk fees, according to the White House.
